ASH
ASH Conference Media
Saturday 7th December
A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis – Catalyst Trial Results
Download Poster –
1_CATALYST-ASH-Poster-2019.pdf
Lenalidomide Maintenance Prolongs Progression-Free Survival and Does Not Impact the Aggressiveness of Clinical Relapse: Data from Long-Term Follow up of the Myeloma XI Trial
Download Poster –
2_TCR-FINAL.pdf
Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial
Download Poster –
3_GHJ-FINAL.pdf
Sunday 8th December
Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia – Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
Download Poster –
4_OPTIMUM_ASH2019.pdf
Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
Download Poster –
5_FITNESS_ASH2019.pdf
Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance
Download Poster –
6_John-SPM-031219-FINAL.pdf
Monday 9th December
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma – Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial
Download Poster –
7_MUKSeven_ASH2019.pdf
Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
Download Poster –
8_ASH-Sex-FINAL.pdf